MedTrace Logo

The Study of Atherosclerosis With Ramipril and Rosiglitazone

NCT00140647 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2008-08-25

No results posted yet for this study

Summary

The purpose of this study is to determine if ramipril and/or rosiglitazone retard the progression of atherosclerosis as evaluated by serial carotid intermedial thickness measurements.

Conditions

Interventions

DRUG

Ramipril

DRUG

Rosiglitazone

Sponsors & Collaborators

  • Heart and Stroke Foundation of Ontario

    collaborator OTHER

  • Gerstein, Hertzel, MD

    lead INDIV

Principal Investigators

  • Eva Lonn, MD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-07-31
Completion
2006-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00140647 on ClinicalTrials.gov